Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Amgen to Acquire Gene-Hunting Firm

By BiotechDaily International staff writers
Posted on 07 Jan 2013
Biotechnology giant Amgen (Thousand Oaks, CA, USA) is set to acquire deCODE Genetics (Reykjavik, Iceland), a global leader in analyzing and understanding the human genome.

The acquisition is intended to bolster Amgen’s drug discovery efforts by developing drugs based on human genetic discoveries, which have had a better track record than drugs developed by animal models that often do not work. deCODE Genetics, founded in 1996, has discovered genetic risk factors for dozens of diseases, ranging from cardiovascular disease to schizophrenia, cancer, and numerous other diseases. In 2012 alone, the company published studies on a rare mutation that protects people from getting Alzheimer’s disease and a study suggesting that older men are more likely to father children with autism.

In January 2010 most of deCODE genetics assets were purchased by Saga Investments (Akureyri, Iceland) an investment company whose owners include Polaris Venture Partners and ARCH Venture Partners, with the intention of continuing most services and retaining the management team. The all-cash transaction values deCODE Genetics at USD 415 million (subject to customary closing adjustments), and does not require regulatory approval. The acquisition is expected to close before the end of 2012.

“deCODE Genetics has built a world-class capability in the study of the genetics of human disease; this capability will enhance our efforts to identify and validate human disease targets,” said Robert A. Bradway, president and CEO at Amgen. “This fits perfectly with our objective to pursue rapid development of relevant molecules that reach the right disease targets while avoiding investments in programs based on less well-validated targets.”

“One of the ways to truly realize the full value of human genetics, is to make our research synergistic with drug development efforts where target discovery, validation, and prioritization efforts can be accelerated,” said Kari Stefansson, MD, founder and CEO of deCODE Genetics. “We believe Amgen's focus and ability to incorporate our genetic research into their research and development efforts will translate our discoveries into meaningful therapies for patients.”

In the late 1990s deCODE collected medical records and genealogical and genetic data of the entire population of Iceland (which numbered 270,000 at the time), creating the Icelandic Health Sector Database (HSD). The HSD became very controversial, and prompted both national and international criticism for its approach to the concepts of privacy and consent. A legal judgment from the Icelandic Supreme Court in November 2003 effectively killed off the HSD project.

Related Links:
Amgen
deCODE Genetics


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.